PSNL Stock Summary and Trading Ideas (Personalis | NASDAQ:PSNL)

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Personalis trades on the NASDAQ stock market under the symbol PSNL.

As of October 20, 2026, PSNL stock price climbed to $15.94 with 2,083,803 million shares trading.

PSNL has a beta of 1.25, meaning it tends to be more sensitive to market movements. PSNL has a correlation of 0.03 to the broad based SPY ETF.

PSNL has a market cap of $1.70 billion. This is considered a Small Cap stock.

Last quarter Personalis reported $22 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.04.

In the last 3 years, PSNL traded as high as $18.89 and as low as $.89.

The top ETF exchange traded funds that PSNL belongs to (by Net Assets): VTI, IWM, ARKG, VXF, IWN.

PSNL has outperformed the market in the last year with a return of +74.6%, while the SPY ETF gained +16.9%. However, in the most recent history, PSNL shares have underperformed the stock market with its stock returning +3.6% in the last 3 month period and -2.8% for the last 2 week period, while SPY has returned +3.7% and -0.7%, respectively.

PSNL support price is $15.63 and resistance is $16.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PSNL shares will trade within this expected range on the day.